EP02.02-007 Correlation between Biological Equivalent Dose and Radiological Changes after Lung Stereotactic Ablative Radiation Therapy

Abstract

Stereotactic ablative radiation therapy (SABR) is the standard of care for inoperable early-stage NSCLC offering excellent local control. Although the related probability of grade ≥2 toxicities is low, 60-100% of the patients present radiological toxicities. Even though these changes may not lead to direct clinical consequences, some are associated with future clinical toxicities and long-term patient management challenges. In this study, we evaluated radiological changes after SABR and correlated them with the received Biological Equivalent Dose (BED).